Many challenges face developers of drugs for rare diseases, including the small number of patients available for clinical trials, genotypic and phenotypic diversity within a disorder, poorly ...

Weight-loss and diabetes drugs like Ozempic have exploded in popularity, but high prices and limited insurance coverage have ...

While it would be presumptuous to base conclusions solely on the number of drugs the FDA approved in 2025, it is noteworthy that FDA nods of new treatments fell short of previous years, though a surge ...

Add Yahoo as a preferred source to see more of our stories on Google. Nitrosamines are by-products of many common chemical reactions. FatCamera/iStock via Getty Images Plus A generic blood pressure ...

Following threats from the Food and Drug Administration (FDA) that it would take "decisive" action against companies selling "illegal copycat drugs," telehealth company Hims & Hers announced it would ...

Illustration of New Drug Application paperwork surrounded by pills, vials, and DNA. The US Food and Drug Administration approved 46 new molecular entities in 2025. Credit: C&EN/Shutterstock The year ...

WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...

The US Food and Drug Administration’s longtime oncology chief has filed to retire from the agency just weeks after he was chosen to lead the FDA’s drug division, according to four people familiar with ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...